Antidepressant Treatments and Cognitive Function of Bipolar Patients
The Impact of Systemic Antidepressant Treatments in Early Stage on Neurocognitive Function of Euthymic Patients With Bipolar Depression
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Chenghao Yang, Doctor
- Phone Number: +86 13752539531
- Email: yts83420@163.com
Study Locations
-
-
-
Tianjin, China
- Recruiting
- Tianjin Anding Hospital
-
Contact:
- Jie Li, Doctor
- Email: jieli@tjmhc.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- A diagnosis of BD diagnosed according to the Diagnostic and Statistical Manual of Mental disorders, Fourth Edition (DSM-IV-TR) diagnosed with Structured Clinical Interview for DSM-IV (SCID); a current state of euthymia is defined by both scores of Montgomery-Åsberg Depression Scale (MADRS) and Young Manic Rating Scale (YMRS) <7, lasting for 4 weeks at least before recruitment
- Initiated with a depressive episode
- Aged between 18~50 years
- Patients comply with all procedures of study
- Participants must sign the informed consent
Exclusion Criteria:
- A history of psychiatric symptoms
- A comorbidity of attention deficit and hyperactivity disorder (ADHD)
- Neurological trauma or neurological diseases which could cause cognition injury
- History of substance dependence/abuse
- Received modified electroconvulsive therapy (MECT) in the past 12 months
- Severe physical disease affecting cognitive function or increasing peripheral NSE
- Recent drug use that affects cognition, such as tricyclic antidepressants, anticholinergic drugs, amphetamines, etc.
- IQ <70
- Use benzodiazepines 4 hours before scale evaluation
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
antidepressant treatment group
participants who had received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
|
|
non-antidepressant treatment group
participants who had not received systemic antidepressant (consecutive treatment with adequate antidepressants for 6 weeks at least)treatment in the early stage (from initial depressive onset to first manic/hypomani episode).
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Subjective cognitive measures
Time Frame: before 11AM
|
cognitive complaints in Bipolar Disorder Rating Assessment (COBRA)
|
before 11AM
|
|
Objective cognitive measures
Time Frame: before 11AM
|
the Stroop Color and Word Test (SCWT), the categorical verbal fluency test (CVFT) (animal naming), and the Trail Making Test Part B (TMT-B), the Digital Span Forward and Backward subtest (DSFB) and the Digit Symbol Coding subtest (DSC) of the Wechsler Adult Intelligence Scale-Revised by China (WAIS-RC) and Trail Making Test Part A (TMT-A), the Visual Reproduction subtest (VRP) and the Visual Recognition subtest (VRC) of the Wechsler Memory Scale-Revised (WMS-R)
|
before 11AM
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Global Assessment Function (GAF)
Time Frame: before 11AM
|
to assess patients' functions psychologically, socially and professionally
|
before 11AM
|
|
Methods Checklist on Quality of Life issued by World Health Organization-Brief version,WHOQOL-BRIEF
Time Frame: before 11AM
|
to assess the quality of life
|
before 11AM
|
|
Peripheral neuron-specific enolase (NSE)
Time Frame: before 11.30AM
|
to test the potential injury of neuron
|
before 11.30AM
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pittsburgh Sleep Quality Index,PSQI
Time Frame: before 11AM
|
to evaluate the quality of sleep
|
before 11AM
|
|
Positive and Negative Affect Scale,PANAS
Time Frame: before 11AM
|
to detect the change in positive and negative affect
|
before 11AM
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chenghao Yang, Doctor, Tianjin Anding Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- TJAH2020-18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Supporting Information Type
- Study Protocol
- Statistical Analysis Plan (SAP)
- Informed Consent Form (ICF)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.